Advaxis Zips Listeria/Opdivo Combo Straight To Registrational Cervical Cancer Trial
Executive Summary
Potentially registrational trial of ADXS-DUAL Listeria-based vaccine with Bristol's PD-1 inhibitor Opdivo in recurrent metastatic cervical cancer will complement Advaxis's adjuvant study of earlier-generation candidate axalimogene filolisbac.
You may also be interested in...
Advaxis Immunotherapy Boosts 12-Month Survival In Cervical Cancer
Advaxis Inc. reported that 38.5% of advanced cervical cancer patients – a group that normally survives for four to seven months on average – survived for at least 12 months after treatment with the company's immunotherapy axalimogene filolisbac (ADXS-HPV) in the first stage of a 67-patient, investigator-initiated, two-stage Phase II clinical trial.
China, Emerging Markets In Focus For Genentech On Broad Avastin Access In Cervical Cancer
U.S. FDA approval is fifth indication for Roche/Genentech’s Avastin. The number of cases in the U.S. is low and set to decline with better prevention, but disease is still considered a major global health problem.
Advaxis to fund combination trial with AstraZeneca's MEDI4736
AstraZeneca's MedImmune subsidiary has entered a clinical trial collaboration with US biotechnology company Advaxis aimed at boosting the companies' distinct investigational cancer immunotherapies by administering them together.